Baiju R. Shah is the President of BioEnterprise. He focuses primarily on BioEnterprise’s medical device and health care services companies. For those clients, Shah counsels on strategic, business development, and operational matters as well as on growth financing.  Shah came to BioEnterprise from McKinsey & Company, where he played a leading role in both the Growth and Business Building and the Economic Development practices.  Shah received a J.D. from Harvard Law School and a B.A. from Yale University.

Jim Scozzie has an extensive background in biopharmaceutical research, development, and commercialization. Scozzie leads the company’s biopharmaceuticals team, both advising current companies and leading the evaluation and development of new biopharmaceutical company opportunities.  Most recently, Scozzie was a Founder and President of Ricerca, a contract R&D company supporting the commercialization of new drugs and biomedical devices and other life science targeted products. Scozzie received his Ph.D. in Chemistry from Case Western Reserve University and his B.A. at Gannon University. 

Bob Baxter leads strategic planning, alliances, and administrative operations. He has spent more than 30 years in the private sector, most recently as Vice President of the Regulatory Studies business unit of Ricerca, a contract drug development company. In this position, he was responsible for the pre-clinical testing necessary for FDA IND/NDA submittals. Baxter received a M.S. degree in Chemical Engineering from Ohio State University and a B.S. degree in Chemical Engineering from the University of Detroit.

Carol Clark leads the company’s effort for advising growth stage health care opportunities including acquisition-based approaches. Clark brings 20 years of experience in structuring and syndicating complex leveraged buyouts, acquisition financings and business expansion facilities at the Bank of Boston and Aetna Life & Casualty.  Recently she was involved as a founding officer and Board member in the creation of NineSigma, a Cleveland-based technology start-up. She served as the company's CFO, was a key member of the private equity fund raising team and remains on the Board.  Clark, a CFA, received an M.B.A. from Cornell University and B.A. from Wesleyan University.

Bob Johnson is a leader of the medical devices team at BioEnterprise. He has an extensive background in the medical device industry across many functions including new ventures, marketing and business development. Johnson has commercialized devices, instrumentation, and diagnostic technologies for cardiology, radiology, obstetrics/gynecology, pulmonology and urology applications. In addition, he has completed numerous transactions including financings, acquisitions, licenses and strategic alliances in his work. Throughout his career, Mr. Johnson has worked in executive capacities for medical device companies including C.R. Bard, Respironics, and Mallinckrodt. Johnson has a B.S. in Business Administration from Loyola University in Baltimore, Maryland.

Jim Weisman leads BioEnterprise’s efforts in serving and developing start-up health care software and service opportunities.  He brings almost 20 years of experience in general management, having worked in senior management at PepsiCo and Macy’s as well as consulting to major financial institutions while with the First Manhattan Consulting Group.  Weisman served on the management team of HealthSync, a start-up company developing marketplaces for defined-contribution based corporate sponsored health insurance.  He has worked with Glengary Ventures, a fund focused on technology based companies, and provided consulting and executive management services to early-stage companies in the biotech and satellite communications industries.  Weisman received his B.S. in Economics from The Wharton School at the University of Pennsylvania and his Executive MBA from Case Weatherhead School of Management.

Glen Gaughan focuses on developing and supporting biopharmaceutical companies for BioEnterprise. He works closely with a number of the companies, supporting the development of their business strategies and operating plans. Gaughan has almost 20 years of experience as a drug discovery scientist with Bristol-Myers Squibb. In roles ranging from Principal Investigator to Group Leader, he contributed to programs searching for new medications for pain, obesity, sleep disorders, and depression, and for contrast agents for MRI.  Gaughan designed ProHance, an MRI contrast agent marketed by Bracco.  Gaughan holds a Ph.D. in Chemistry from the University of Oregon, an MBA from Case Weatherhead School of Business, and a B.A. from Dartmouth College.

Meg Groh focuses on supporting biopharmaceutical companies and also oversees the due diligence process for new opportunities. She has extensive research experience at the Jefferson Institute of Molecular Medicine, Howard Hughes Medical Institute, the University of Chicago and Case Western Reserve University. Her work covered several areas of molecular medicine including lipid metabolism, molecular cardiology, and stem cell biology. Groh received a Ph.D. from the University of Chicago, a B.S. from Tulane University and is completing an M.B.A. at Case Western.

Aram Nerpouni focuses on healthcare service and software companies. He brings over 10 years of experience in international market development and management. Nerpouni consulted with U.S. companies on sales, marketing and distribution strategies for entering new markets in Europe, Asia and Latin America. He also worked as a Director of Marketing at The Bonne Bell Company, where he was a member of the corporate leadership team and was responsible for new market development, brand management, new category development and licensing. Early in his career, Nerpouni also worked with an executive search firm whose services included management assessment and development. Nerpouni received his Executive MBA from Case Weatherhead School of Management and a B.S. in Biology from Stanford University.

Denise Richardson serves as a Director of Business Development, overseeing BioEnterprise's due diligence review of opportunities and the development of a network of regional resources to support health care company growth. Her corporate experience includes managing the Microbiology laboratory for Mogul Corporation, then a division of Dexter Corp.  She was also the Vice President of Regulatory Affairs for United States Biochemical (USB) and Director of Regulatory Affairs for Amersham Pharmacia Biotech.  Richardson has worked in research laboratories at the University of California, Santa Barbara (UCSB), Harvard University Medical School, and Eli Lilly.  Richardson received her B.S. degree in Microbiology, with highest distinction, from Purdue University, and her M.S. in Marine Biology from Boston University.

Karen Spilizewski is a leader of BioEnterprise's medical device team and is also a Vice President with RiverVest Ventures. She brings nearly 20 years of experience in new product development and business development in medical and non-medical technologies. Spilizewski worked as a business development manager at Avery Dennison and in product development roles ranging from research manager to associate. She was responsible for conducting marketing, financial, technical, and competitive analyses of new opportunities for microelectronic, biomedical, optical display, and MEMs applications. In product development roles, she has developed and commercialized products for various medical devices, including wound care, diagnostics, surgical, and electromedical applications. Spilizewski received her MBA at Case Weatherhead School of Management, and both an M.S. in Macromolecular Science and a B.S. degree in Biomedical Engineering from Case Western Reserve University.

Nancy Rubin serves select BioEnterprise companies as an Acting CFO. For more than ten years, Rubin has served as a contract financial and administrative specialist working in financial, administrative, and operational assessment and development for early stage to medium-sized companies. Her clients have included biopharmaceutical, medical device, healthcare, manufacturing, telecommunications, distribution, and professional service companies, including Osiris Therapeutics. Rubin has also worked in a variety of financial capacities for companies including TRW, American Specialty Foods, and Ottosensors.

Jon Snyder is a CEO In Residence at BioEnterprise. He has over 20 years of management experience in biomedical and healthcare sales and marketing with significant experience in bringing new products into the marketplace. Jon's background covers business development, product development, market management, and sales management. He has helped launch and manage products in the neurology, neurosurgery, urology, gynecology, gastroenterology, plastic surgery, spine, endoscopy, sterilization, and infection prevention markets at small and large companies including Cyberonics, Cardinal Health, Imalux, and Steris. Snyder has a B.S. in Communication from Ohio University.

Raymond E. Ursick has been a Regulatory Affairs and Quality Systems professional for over 25 years.  He has obtained FDA approvals for diagnostic imaging devices, cardiovascular devices and implants, sterilization and other infection control devices, surgical devices, electronic pain management and therapy devices, and critical care monitoring equipment. Additionally, he has led successful programs to achieve ISO 9001/EN46001, ISO 13485 certification, to obtain CE Marking, and to achieve Quality Awards using Malcolm Baldridge criteria.  Ursick has held executive positions at three Johnson & Johnson operating companies (Technicare, Critikon, and Interventional Systems) and at STERIS as Vice President, Regulatory Affairs and Quality Systems.

Bill Poore manages finance and administration functions for both BioEnterprise and BioOhio. The functions include financial projections and statements, grants managements, accounting, personnel administration, and general operations. He brings over 30 years of experience in these areas to BioEnterprise. Poore holds both an MBA in Finance and a BBA in Accounting from Cleveland State University.

Annette Ballou leads strategic marketing for BioEnterprise, helping the initiative and its companies in market positioning, message definition, and communication strategy. Ballou has over 20 years of experience in healthcare marketing and business development in a range of private companies. She has expertise in strategic planning and implementation, business development, marketing, communications and operations, Ballou received her J.D. from Southern Methodist University as well as a B.A. in English and a B.S. in Psychology.

Laurie Toth is the marketing manager at BioEnterprise. In this capacity she performs industry market research, produces the quarterly electronic newsletter, facilitates events and conferences and manages the website and IT systems. Ms. Toth received her BA in Business Administration from Baldwin-Wallace College in Berea, Ohio.

Jekkie Kim is a physician currently pursuing a J.D./M.B.A. dual-degree at Case Western Reserve University. She received her M.D. and Masters in Law (LL.M.) from Yonsei University, Korea and received her medical training from Seoul National University Hospital. She has practiced as a primary physician in private clinics and also as a consultant for universities, Hospitals, and Insurance companies.

Sameer V. Kulkarni, MD, is a business development associate with 9 years experience in hospital management, clinical research and business development. Dr. Kulkarni received his MD from B.J. Medical College in Pune, India and is currently pursuing his MBA at Case Western Reserve University. Prior to joining BioEnterprise, Dr. Kulkarni held the position of Manager-Quality Assurance in Clinical Trials for Chest Research Foundation and Project Manager - Rural and Tribal Development and Research Institute (RATDARI). He is well versed with FDA regulations and the overall process of drug development.

Yingli Wolinsky holds a Ph.D. degree in cellular and molecular biology from Kent State University and an MBA from CWRU Weatherhead School of Management. As a Business Development Associate, she is directly involved in the review of opportunities, market research, and due diligence. For seven years, Dr. Wolinsky was a key member of the transgenic and targeting facility at CWRU School of Medicine. Prior to her CWRU experience, Dr. Wolinsky held an internship position at the Delphi Corporation, Shanghai Division, Packard Electric Systems.